HC Wainwright's Estimate for ACRV FY2029 Earnings

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) has recently had its FY2029 earnings estimates analyzed by HC Wainwright. In their report published on March 26, 2025, analyst E. Bodnar projected that Acrivon will report earnings per share (EPS) of ($1.25) for fiscal year 2029. Additionally, HC Wainwright has assigned a "Buy" rating to the stock, along with a price target of $19.00.

In comparison, the broader market consensus for Acrivon Therapeutics' full-year earnings has been estimated at ($2.49) per share. This discrepancy highlights a potentially more optimistic outlook from HC Wainwright regarding the company's future performance.

Other analysts have shown interest in the company, with KeyCorp initiating coverage on January 31, 2025, offering an "overweight" rating. Similarly, Cantor Fitzgerald reaffirmed an "overweight" rating in their latest research note. Current data indicates that a total of eight research analysts have rated Acrivon Therapeutics stock with a "Buy" rating. Collectively, the stock has an average rating of "Buy" and a consensus price target of approximately $23.17.

Market Performance for Acrivon Therapeutics

As of Thursday, March 27, 2025, shares of NASDAQ:ACRV were priced at $2.24, reflecting a decline of 11.1%. The stock's moving averages show a fifty-day average of $5.35 and a two-hundred-day average of $6.53. Over the past year, Acrivon has seen a low of $2.14 and a high of $11.90, positioning its market capitalization at $69.74 million and a P/E ratio of -0.83.

Recently, Acrivon Therapeutics reported its quarterly earnings, revealing an EPS of ($0.60), which was an improvement over the consensus estimate of ($0.66) by $0.06.

Institutional Investment in Acrivon Therapeutics

In recent months, various institutional investors have made adjustments to their holdings in Acrivon. Barclays PLC increased its stake by 51.2% during the third quarter, now holding 33,306 shares valued at $233,000. Also, State Street Corp raised its position by 26.4%, now owning 225,896 shares valued at about $1.58 million. Moreover, JPMorgan Chase & Co. boosted its stake by a notable 548.3% during the same period, acquiring an additional 28,748 shares. Other notable transactions include Exome Asset Management LLC establishing a new position worth approximately $817,000 and China Universal Asset Management Co. Ltd. acquiring shares valued at around $40,000. Overall, institutional investors and hedge funds now own 71.62% of the company’s stock, demonstrating significant interest and confidence in Acrivon Therapeutics.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative oncology treatments. The company employs a unique proteomics-based patient responder identification platform, known as Acrivon Predictive Precision Proteomics, to match specific drugs to patients who are most likely to benefit from them. This approach includes the development of proprietary OncoSignature companion diagnostics to enhance treatment outcomes for cancer patients.

ACRV, Earnings, Estimates